Latest News and Press Releases
Want to stay updated on the latest news?
-
SparingVision Reaches Final Dose Escalation Step in PRODYGY Trial with SPVN06 for retinitis pigmentosa Positive recommendation received from the Data Safety Monitoring Board (DSMB) enabling...
-
SparingVision Reports Positive Initial Safety Data from the first cohort treated in its PRODYGY Phase I/II Gene Therapy Trial Lead gene therapy asset, SPVN06, reported to be well-tolerated in first...
-
SparingVision sells ex vivo GIRK technology to Tenpoint Therapeutics SparingVision remains focused on in vivo genomic medicines, with SPVN20, a GIRK-based gene therapy candidate, expected to reach...
-
SparingVision Strengthens Leadership Team with the Appointment of Dr Mehdi Gasmi as Chief Operating Officer Raffaella Toso, PhD, joins as VP Corporate Development & Alliance Management and...
-
SparingVision Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting Paris, March 19, 2021 – SparingVision (“the Company”), a genomic...
-
SparingVision Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting Paris, March 19, 2021 – SparingVision (“the Company”), a genomic...
-
Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board Development of lead asset SPVN06 to further benefit from high-level Clinical Advisory Board ...
-
Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board Development of lead asset SPVN06 to further benefit from high-level Clinical Advisory Board ...